To investigate whether the inhibition of Ezh2 is sufficient to promote the transcriptional activation of the specific set of GSK126-regulated genes in tumor cells or additional signaling is required, we generated RNA-seq profiles of KrasG12D;Trp53−/− NSCLC cells in vitro and compared these profiles to those from the in vivo setting. The gene discussed is TP53; the disease is non-small cell lung carcinoma.